Lu177DOTATATETherapyQualityChecker
Lu-177 DOTATATE Therapy Quality Checker
Lu-177 DOTATATE Therapy Quality Checker — Quality control of Lu-177 DOTATATE for PRRT
ℹ️ Utility checks critical parameters of Lu-177 DOTATATE:
- Radiochemical purity (≥95%)
- Free lutetium (≤2%)
- Precursor residue (<0.1%)
- Specific activity (≥20 GBq/mg)
- Lu-177m impurity (<0.01%) — CRITICAL!
⚠️ CRITICAL: Lu-177m (T½=160 days) creates long-term radiation burden!
Lu-177 DOTATATE is used for PRRT (neuroendocrine tumor therapy).
High specific activity is necessary for effective receptor binding.
Usage
Lu177DOTATATETherapyQualityChecker.exe → demo mode (console output)
Lu177DOTATATETherapyQualityChecker.exe input.csv output.json → evaluate your data
Input format
BatchNumber,RadiochemicalPurityPercent,FreeLutetiumPercent,PrecursorPercent,SpecificActivityGBq_per_mg,pH,ResidualSolventsPPM,EndotoxinsEU_per_mL,SterilityTest,ActivityGBq,RadionuclidicPurityPercent,Lu177mImpurityPercent
Example
LU177-DOTATATE-THER-2026-001,99.0,0.5,0.05,40.0,5.0,100.0,10.0,0,7.4,99.99,0.0005
— WHY IS THIS NEEDED?
Lu-177 DOTATATE (Lutathera) is standard therapy for neuroendocrine tumors (NETs).
- Binds to somatostatin receptors (SSTR2).
- Lu-177 emits beta particles for therapy and gamma quanta for imaging.
- Half-life 6.65 days.
- Requires high radiochemical purity and specific activity.
⚠️ CRITICAL:
- Radiochemical purity ≥95% — guarantee of dose delivery to tumor.
- Free lutetium ≤2% — free ions accumulate in bones and liver.
- Precursor residue <0.1% — unreacted peptide competes for receptors.
- Specific activity ≥20 GBq/mg — necessary for high contrast and efficacy.
- Lu-177m impurity <0.01% — Lu-177m is long-lived and creates unnecessary radiation burden.
- pH 4.5-6.5 — optimal media for Lu-DOTA complex stability.
- Residual solvents must be minimal (<500 ppm).
- Endotoxins <175 EU/mL — standard for parenteral drugs.
- Sterility — MANDATORY.
Key features
- Strict control of Lu-177m impurity characteristic of reactor production.
- Assessment of residual precursor, critical for therapy efficacy.
- Specific activity check for effective targeting.
- Compliance with GMP and Pharmacopoeia requirements for Lu-177 radiopharmaceuticals.
- Comprehensive safety check (endotoxins, sterility, pH, solvents).
Critical parameters
- Radiochemical purity: ≥95.0%
- Free lutetium: ≤2.0%
- Precursor residue: <0.1%
- Specific activity: ≥20.0 GBq/mg
- Radionuclidic purity: ≥99.9%
- Lu-177m impurity: <0.01%
- Residual solvents: <500 ppm
- pH: 4.5–6.5
- Endotoxins: <175 EU/mL
- Sterility: no growth
💡 Usage tips:
1. Radiochemical purity determined by TLC or HPLC.
2. Lu-177m impurity controlled by gamma spectrometry.
3. Synthesis usually performed on automatic modules or manually using kits.
4. Drug is stable for several days due to strong DOTA complex.
5. Lu-177 emits gamma quanta 208 and 113 keV, allowing post-therapeutic imaging.
⚠️ Note: Lu-177 DOTATATE represents successful theranostics example (therapy + diagnostics). Quality control here is critical as error in dosing or purity can lead either to treatment inefficacy or serious toxicity to kidneys and bone marrow.
input.csv
BatchNumber,RadiochemicalPurityPercent,FreeLutetiumPercent,PrecursorPercent,SpecificActivityGBq_per_mg,pH,ResidualSolventsPPM,EndotoxinsEU_per_mL,SterilityTest,ActivityGBq,RadionuclidicPurityPercent,Lu177mImpurityPercent LU177-DOTATATE-THER-2026-001,99.0,0.5,0.05,40.0,5.0,100.0,10.0,0,7.4,99.99,0.0005 LU177-DOTATATE-THER-2026-002,97.0,1.5,0.08,35.0,4.8,200.0,20.0,0,7.0,99.95,0.0008 LU177-DOTATATE-THER-2026-003,90.0,5.0,0.2,25.0,6.0,600.0,50.0,1,6.5,99.50,0.0020
URS & FS — user requirements and functional specification
URS — User Requirements Specification
- The utility shall accept
input.csvwith these mandatory columns:BatchNumber,RadiochemicalPurityPercent,FreeLutetiumPercent,PrecursorPercent,SpecificActivityGBq_per_mg,pH,ResidualSolventsPPM,EndotoxinsEU_per_mL,SterilityTest,ActivityGBq,RadionuclidicPurityPercent,Lu177mImpurityPercent. - Each row shall be processed as a separate batch or record identified by
BatchNumber. - Before evaluation, the utility shall validate the CSV structure, mandatory values, numeric fields and allowed text values.
- Rules and limits shall be applied to every parameter in the input row.
- Critical violations identified in the supplied description shall set the record result to FAIL.
- Each row shall receive an overall PASS, WARNING or FAIL status with the triggered rules.
- An invalid row shall not receive PASS.
output.jsonshall contain source values, applied limits, individual check results and errors.- The same input and the same rule profile shall produce the same result.
FS — Functional Specification
- Run
Lu177DOTATATETherapyQualityChecker.exein demonstration mode or withinput.csv output.jsonarguments. - Read UTF-8 CSV and verify the exact set of mandatory columns.
- Convert row values to numeric and text types.
- Apply the rules defined in the approved version or configuration profile.
- Generate individual check results and derive the overall status from the most severe violation.
- Write machine-readable
output.json. - Structural and type errors shall be reported explicitly and shall not be masked by a successful status.
Complete input.csv example
BatchNumber,RadiochemicalPurityPercent,FreeLutetiumPercent,PrecursorPercent,SpecificActivityGBq_per_mg,pH,ResidualSolventsPPM,EndotoxinsEU_per_mL,SterilityTest,ActivityGBq,RadionuclidicPurityPercent,Lu177mImpurityPercent LU177-DOTATATE-THER-2026-001,99.0,0.5,0.05,40.0,5.0,100.0,10.0,0,7.4,99.99,0.0005 LU177-DOTATATE-THER-2026-002,97.0,1.5,0.08,35.0,4.8,200.0,20.0,0,7.0,99.95,0.0008 LU177-DOTATATE-THER-2026-003,90.0,5.0,0.2,25.0,6.0,600.0,50.0,1,6.5,99.50,0.0020
Purpose of the supplied test rows
- The first row contains values consistent with the criteria stated in the supplied description.
- The second row contains values closer to the limits or moderate deviations.
- The third row contains clear deviations for negative-result testing.
Minimum output.json structure
{
"utility": "Lu177DOTATATETherapyQualityChecker",
"source": "input.csv",
"results": [
{
"batchNumber": "BATCH-001",
"status": "PASS",
"checks": [
{
"parameter": "ParameterName",
"value": 0,
"limit": "configured rule",
"status": "PASS"
}
],
"errors": []
}
]
}
Minimum OQ scenarios
- Process the complete supplied
input.csv. - Remove a mandatory column and confirm a contract error.
- Provide text instead of a numeric value and confirm a type error.
- Test values directly on the configured limits.
- Repeat the run with the same input and confirm an identical result.
Before operational use
- Reconcile rules and limits with the approved specification, methods and SOP.
- Fix the executable version and rule-profile version.
- Retain the source CSV together with the generated JSON.
Included in packages
Endocrinology QC Suite
QC package for endocrinology: thyroid, pituitary/peptide hormones, corticosteroids, sex hormones and selected metabolic medicines.
OpenPetRad QC Suite
A specialised utility package for radiopharmaceutical quality control: PET, SPECT, therapeutic radionuclides, generators and decay calculations.
OpenPetRad3: expanded PET/SPECT and radiopharmaceutical QC package
A curated suite for PET/SPECT radiopharmaceuticals, generator and cyclotron radionuclides, labelled compounds, radiochemical purity, breakthrough, sterility and endotoxin control.
OpenRadioligand & Theranostics Expansion QC Suite
Radioligand & Theranostics Expansion QC Suite: FUZKK utility package for CSV→JSON QC checks with EU-first limit priority.
OpenRadiopharmaceutical Diagnostics and Therapy QC Suite
36 utilities for clinically oriented radiopharmaceutical and workflow quality control: PET/SPECT tracers, the Tc-99m renal workflow, PRRT, PSMA therapy, targeted alpha therapy, radioembolization, bone-pain palliation, immuno-PET and generator-based radionuclide control.
OpenRPH isotope family: beta-emitting therapy
Lu-177, Y-90, Ho-166, Re-188, Sm-153, Sr-89, P-32, Cu-67 and Tb-161.
OpenRPH organ/system: bone and musculoskeletal
Bone scintigraphy, MDP/PYP, marrow, bone-pain palliation, skeletal metastases and radiosynovectomy.
OpenRPH organ/system: brain and CNS
Brain perfusion, dopamine transporter, amyloid/tau, receptor imaging and neurological SPECT/PET.
OpenRPH organ/system: endocrine, thyroid and NET
Radioiodine, thyroid/parathyroid, somatostatin receptor, MIBG and neuroendocrine workflows.
OpenRPH organ/system: hepatobiliary and GI
HIDA, mebrofenin, gallbladder, gastric emptying, GI transit, bleeding and liver/spleen imaging.
OpenRPH organ/system: oncology and theranostics
Tumour imaging, PSMA/FAPI/receptor tracers, immuno-PET, targeted radionuclide therapy and radioembolization.
OpenRPH organ/system: renal and urinary
Renography, GFR/ERPF, renal uptake, DMSA/MAG3/DTPA and bladder-related workflows.
OpenRPH use case: radionuclide therapy and theranostics
Lu-177, Ac-225, Ra-223, Y-90, Ho-166, Sm-153, Sr-89, Re-188, Tb-161, I-131 and other therapeutic radiopharmaceuticals: activity, purity, free metal, daughters and toxicological constraints.
OpenRPH workflow: generators and isotope purity
Generator eluate, breakthrough, radionuclidic purity, isotope mix and starting radionuclides.
OpenRPH workflow: imaging QC and quantitative interpretation
Acquisition, uptake, clearance, perfusion, transit, ejection fraction, segmentation and quantitative imaging.
OpenRPH workflow: product release QC
Assay, purity, sterility, endotoxins, pH, impurities, appearance and batch-release checks.
OpenRPH workflow: stability, storage, decay and waste
Kinetic stability, shelf life, decay correction, expiry, storage, trend and radioactive waste.
OpenRPH workflow: synthesis, labelling and kit reconstitution
Radiolabelling, synthesis, chelation, reducing agent, pH/stoichiometry and kit preparation.
OpenRPH: combined radiopharmaceutical QC package
RPH combines PetRad, PetRad2 and PetRad3 into one umbrella package for PET/SPECT, therapeutic radionuclides, generators, labelled compounds, decay calculations, sterility, endotoxins and radiochemical/radionuclidic purity.
Open